News
May 26, 2026: Maryland PDAB passes a price cap on Ozempic, as Virginia’s governor questions board efficacy
Ozempic, the second drug that the state has set an upper payment limit on, will be capped at $274 for a 30-day supply.
[...]May 18, 2026: FDA warns 503B compounding pharmacy for producing tirzepatide after shortage ended
The ProRx warning letter signals increased FDA scrutiny of compounded weight loss product that are not intended to be compounded in the US.
[...]Safety risks in the GLP-1 market: an update on weight loss medication, May 2026
Criminal counterfeiters are exploiting Americans’ demand for blockbuster diabetes and weight loss drugs made with semaglutide and tirzepatide, while compounders, telehealth companies, and med spas strain and skirt public health measures to meet high demand.
[...]An Arkansas newspaper printed an ad hawking foreign drugs. Are foreign “pharmacies” advertising in your local newspaper?
An Arkansas newspaper printed an ad hawking foreign drugs. Are foreign “pharmacies” advertising in your local newspaper? On May 18, 2026, PSM sent a letter rebuking the Arkansas Democrat-Gazette for selling ad space to a Canadian online pharmacy last month. The advertisement, which promised to “save buyer’s up to 80% on their prescription drugs,” promotes…
[...]May 11, 2026: Connecticut AG’s crackdown leads to major platform halting sales of “research grade” weight loss chemicals to U.S.
In a major settlement, Made-in-China.com will stop selling research chemicals to U.S. buyers following an investigation by Connecticut’s Attorney General.
[...]May 4, 2026: FDA moves to restrict large-scale compounding of three weight loss drugs
The FDA proposed restricting three GLP-1 drugs from the 503B bulks list, which would prevent outsourcing facilities from compounding them from raw ingredients without a clear clinical need.
[...]Partnership for Safe Medicines Applauds FDA Action to Curb Unsafe Compounding of GLP-1 Medications
The Partnership for Safe Medicines strongly supports the Food and Drug Administration’s proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list. This action reflects sound science, sound law, and a clear-eyed commitment to patient safety. Full statement inside.
[...]April 27, 2026: Physician who illegally imported weight loss drugs gets probation
The former doctor admitted to buying tirzepatide from a lab in China and distributing it without medical evaluations, and is now being sued by a former hospital employee who alleges the drug caused life-threatening complications requiring major surgery.
[...]Prescription Drug Freight Fraud Report, April 2026
What do FDA records of GLP-1 and antibiotic imports show about freight fraud patterns over the last six months?
[...]What’s master carton smuggling?
In March, customs officers in Cincinnati announced the seizure of thousands of shipments of GLP-1s and other peptides packaged inside more than 300 “master cartons” with deceptive manifests meant to slip into the country unnoticed. Curious how this smuggling scheme works? Read on.
[...]